Cutting Edge: Identification of Neutrophil PGLYRP1 as a Ligand for TREM-1

Christine B. Read(Novo Nordisk (Denmark)), Joseph L. Kuijper(Novo Nordisk (United States)), Siv A. Hjorth(Novo Nordisk (Denmark)), Mark Heipel(Novo Nordisk (United States)), Xiaoting Tang(Novo Nordisk (United States)), Andrew J. Fleetwood(Novo Nordisk (Denmark)), Jeffrey L. Dantzler(Novo Nordisk (United States)), S. Grell(Novo Nordisk (Denmark)), Jesper Kastrup(Novo Nordisk (Denmark)), Camilla Wang(Novo Nordisk (United States)), Cameron S. Brandt(Novo Nordisk (United States)), Anker Jón Hansen(Novo Nordisk (Denmark)), Nicolai Wagtmann(Novo Nordisk (Denmark)), Wenfeng Xu(Novo Nordisk (United States)), Vibeke W. Stennicke(Novo Nordisk (Denmark))
The Journal of Immunology
January 17, 2015
Cited by 153Open Access
Full Text

Abstract

Triggering receptor expressed on myeloid cells (TREM)-1 is an orphan receptor implicated in innate immune activation. Inhibition of TREM-1 reduces sepsis in mouse models, suggesting a role for it in immune responses triggered by bacteria. However, the absence of an identified ligand has hampered a full understanding of TREM-1 function. We identified complexes between peptidoglycan recognition protein 1 (PGLYRP1) and bacterially derived peptidoglycan that constitute a potent ligand capable of binding TREM-1 and inducing known TREM-1 functions. Interestingly, multimerization of PGLYRP1 bypassed the need for peptidoglycan in TREM-1 activation, demonstrating that the PGLYRP1/TREM-1 axis can be activated in the absence of bacterial products. The role for PGLYRP1 as a TREM-1 activator provides a new mechanism by which bacteria can trigger myeloid cells, linking two known, but previously unrelated, pathways in innate immunity.


Related Papers

No related papers found

Powered by citation graph analysis